VIRO Stock Overview
An in vitro diagnostics company, develops and markets prognostic products for the healthcare sector. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
ViroGates A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 14.90 |
| 52 Week High | DKK 31.00 |
| 52 Week Low | DKK 4.98 |
| Beta | 0.78 |
| 11 Month Change | 134.65% |
| 3 Month Change | 148.33% |
| 1 Year Change | 65.92% |
| 33 Year Change | -88.45% |
| 5 Year Change | -55.39% |
| Change since IPO | -82.57% |
Recent News & Updates
Recent updates
ViroGates (CPH:VIRO) Is In A Good Position To Deliver On Growth Plans
Mar 06
We're Hopeful That ViroGates (CPH:VIRO) Will Use Its Cash Wisely
Nov 21Will ViroGates (CPH:VIRO) Spend Its Cash Wisely?
Jun 14We're Not Very Worried About ViroGates' (CPH:VIRO) Cash Burn Rate
Sep 19We Think ViroGates (CPH:VIRO) Can Afford To Drive Business Growth
Apr 14We Think ViroGates (CPH:VIRO) Can Afford To Drive Business Growth
Dec 30
Shareholder Returns
| VIRO | DK Medical Equipment | DK Market | |
|---|---|---|---|
| 7D | -32.3% | -1.5% | -2.1% |
| 1Y | 65.9% | 14.0% | 6.2% |
Return vs Industry: VIRO exceeded the Danish Medical Equipment industry which returned 14.3% over the past year.
Return vs Market: VIRO exceeded the Danish Market which returned 4.2% over the past year.
Price Volatility
| VIRO volatility | |
|---|---|
| VIRO Average Weekly Movement | 25.8% |
| Medical Equipment Industry Average Movement | 3.6% |
| Market Average Movement | 4.2% |
| 10% most volatile stocks in DK Market | 10.4% |
| 10% least volatile stocks in DK Market | 2.5% |
Stable Share Price: VIRO's share price has been volatile over the past 3 months compared to the Danish market.
Volatility Over Time: VIRO's weekly volatility (26%) has been stable over the past year, but is still higher than 75% of Danish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 10 | Jakob Knudsen | www.virogates.com |
ViroGates A/S, an in vitro diagnostics company, develops and markets prognostic products for the healthcare sector. It offers suPARnostic, a proprietary biomarker used in hospital emergency services to support the clinical decision on hospitalization or discharge of acute patients and to identify high-risk sepsis patients at an early stage, as well as used for the prognosis of lifestyle-related diseases, such as cardiovascular disease, type 2 diabetes, and cancer; and for the assessment of longevity and biological age in a non-hospital setting. The company’ products icludes suPARnostic TurbiLatex, a latex particle-enhanced turbidimetric immunoassay that quantitatively determines the soluble urokinase plasminogen activator receptor (suPAR) level in human K2-EDTA- or lithium heparin plasma samples; suPARnostic ELISA that provides fully quantitative results; suPARnostic Quick Triage kit, which is used in the point of care situation for early warning and patient triaging that will allow clinicians and nurses to obtain a fast patient prognosis for patient disease severity, progression and outcome; and suPARnostic POC+, a point-of-care finger prick test that detects the level of suPAR in the blood.
ViroGates A/S Fundamentals Summary
| VIRO fundamental statistics | |
|---|---|
| Market cap | DKK 115.24m |
| Earnings (TTM) | -DKK 13.23m |
| Revenue (TTM) | DKK 7.25m |
15.9x
P/S Ratio-8.7x
P/E RatioIs VIRO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VIRO income statement (TTM) | |
|---|---|
| Revenue | DKK 7.25m |
| Cost of Revenue | DKK 1.80m |
| Gross Profit | DKK 5.45m |
| Other Expenses | DKK 18.69m |
| Earnings | -DKK 13.23m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.71 |
| Gross Margin | 75.22% |
| Net Profit Margin | -182.57% |
| Debt/Equity Ratio | 74.8% |
How did VIRO perform over the long term?
See historical performance and comparison